Register a trial

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03339388




Registration number
NCT03339388
Ethics application status
Date submitted
7/11/2017
Date registered
13/11/2017

Titles & IDs
Public title
Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stone Disease
Scientific title
Multi-Center Feasibility Study of Enhanced Lithotripsy System (ELS) in The Treatment of Urinary Stone Disease
Secondary ID [1] 0 0
2017-03
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urinary Stone 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Enhanced Lithotripsy System

Experimental: Enhanced Lithotripsy System - Treatment of urinary stones with the Enhanced Lithotripsy System


Treatment: Devices: Enhanced Lithotripsy System
Stone treatment with the Enhanced Lithotripsy System
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of study participants with Serious Device and/or Serious Procedure-Related Adverse Events (Safety)
Timepoint [1] 0 0
90 days
Secondary outcome [1] 0 0
Stone-free status
Timepoint [1] 0 0
30 days

Eligibility
Key inclusion criteria
* Male or female aged = 18 years to = 75 years.
* One urinary stone-apparent on a computed tomography (CT) scan within 14 days prior to study enrollment
* Stone size, as estimated by pre-procedure CT, with all dimensions 15 mm or less.
* Provides written informed consent
* Understands and accepts the study requirements
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Age less than 18 years of age or over 75 years of age
* Diagnosis of radiolucent stones
* Diagnosis of stones in the lower pole of kidney
* History of cystinuria
* Urine pH below 5.5
* Current untreated urinary tract infection
* Pregnancy
* Coagulation abnormality or taking prescription anticoagulants. Aspirin usage will be discontinued at least 7 days prior to enrollment at the discretion of the attending physician.
* Mobility issues - unable to comfortably lie still for up to 30 minutes or unable to roll from back to side
* Known hypersensitivity to conductivity gel
* Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.)
* Body mass index greater than 35
* American Society of Anesthesiologists (ASA) score of 3 or greater general anesthesia risk level
* Known sensitivity to possible medications used before, during, or after the ELS procedure, including but not limited to the following: sedative agents, general anaesthetics, topical anaesthetics, and opioid analgesics.
* Enrollment in another research study or previous participation within 30 days of enrollment.

Study design
Purpose of the study
Other
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/12/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/10/2022
Sample size
Target
Accrual to date
Final
13
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
McArthur Urology - Campbelltown
Recruitment hospital [2] 0 0
Westmead Private Hospital - Westmead
Recruitment hospital [3] 0 0
Goldfields Urology - Bendigo
Recruitment hospital [4] 0 0
Austin Health - Melbourne
Recruitment postcode(s) [1] 0 0
2560 - Campbelltown
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
3550 - Bendigo
Recruitment postcode(s) [4] 0 0
3084 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Avvio Medical
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Damien M Bolton, MD, MBBS
Address 0 0
Austin Hospital, Melbourne Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03339388